BVI launches PODEYE hydrophobic monofocal IOL in Japan

News
Article

The IOL launch is the company’s second market debut in less than 12 months.

Intraocular lens taken out of injector Image Credit: AdobeStock/Oktay

Image Credit: AdobeStock/Oktay

BVI has made its second market debut in less than 12 months with its official launch of the PODEYE hydrophobic monofocal intraocular lens (IOL) in Japan, a country known for its hydrophobic market. The new product had been approved by the Japanese Pharmaceuticals and Medical Devices Agency and is now available for commercial use and surgeons, according to a news release. The IOL was unveiled during the Japanese Ophthalmological Society annual meeting in Tokyo, Japan, held from April 18 to 21.1,2

“Our commitment to the Japanese ophthalmic market is a clear priority for BVI. The PODEYE launch continues to execute on our strategic vision and global expansion. We are set to equip surgeons with more solutions to enhance patient care. Anticipate more groundbreaking product launches from us in Japan and many other major markets globally.” said Shervin Korangy, president and CEO of BVI.

The IOL utilizes double C-loop haptic design that is unique to BVI lenses and referred to as “POD.” Additionally, the IOL’s proprietary, hydrophobic GFY material is also specific to BVI, which provides 100% glistening-free material. The POD design was introduced with the launch of the PODEYE hydrophobic IOL in Europe in 2012. The double C-loop design has proven successful with reliable IOL centration and rotational stability, according to the release.

Currently, BVI develops and supplies approximately 20% of IOL material for competing IOL companies global.1 The company’s IPure IOLs are available in B1PC (clear), B1PY (yellow), and B3PC (clear).3 Each type of IOL has high contrast in various lighting conditions and maintains natural corneal depth of focus. IPURE IOLs also have faster average IOL prep and delivery time in comparison to manually loaded IOL delivery systems, according to BVI.3

References:
  1. BVI launches PODEYE hydrophobic monofocal IOL in Japan. News release. BVI. April 18, 2024. Accessed April 23, 2024. https://www.bvimedical.com/us/bvi-launches-podeye-hydrophobic-monofocal-iol-in-japan/
  2. The 128th annual meeting of the Japanese Ophthalmological Society, Department of Ophthalmology, Shinshu University School of Medicine. Japanese Ophthalmological Society. Accessed April 22, 2024. https://www.congre.co.jp/jos2024/en/index.html
  3. IPure Intraocular lenses. BVI. Accessed April 23, 2024. https://www.bvimedical.com/us/intraocular-lenses/ 
Recent Videos
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO; Brianna Rhue, OD, FAAO, FSLS; Ben Casella, OD; and Ben Gaddie, OD, FAAO shared their insights from the conference.
Agatha Sleboda, OD; Arti Shah, OD, FAAO; and Kent J. Nozacki, OD provide the best tips that they give to their patients during natural disasters events in light of the recent Greater Los Angeles wildfires.
Optometrists local to the Los Angeles area overview their efforts to continue providing support to patients affected by January's wildfires.
Brianna Rhue, OD, FAAO, FSLS, reviewed key takeaways from The Future of Myopia Management: Perspectives from Leading Experts talk from SECO 2025.
Dr. Nate Lighthizer shares key takeaways from the SECO Showcase on anterior segment technology and full laser certification course offered at SECO.
Dr. Julie Rodman discusses retina, imaging, and posterior segment in SECO presentations
Robert L. Stamper, MD, overviews his optometric track talk titled Objective Perimetry - Can you see it? at this year's Glaucoma 360 meeting.
Three EnVision Summit faculty members weigh in on the importance of comanagement in glaucoma management, where artificial intelligence will lead eye care, and what hopes are on the horizon for corneal ectasia treatments.
Yvonne Ou, MD, outlined lifestyle modifications for glaucoma management that have proven beneficial, including yoga and cycling.
© 2025 MJH Life Sciences

All rights reserved.